Cart
sales@molnova.com
ABL-IN-29
CAS No. 1430719-97-3
ABL-IN-29( —— )
Catalog No. M11821 CAS No. 1430719-97-3
ABL-IN-29 is a picomolar ABL kinase inhibitor with IC50 of 0.06/0.11 nM for wt ABL and ABL T315I respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameABL-IN-29
-
NoteResearch use only, not for human use.
-
Brief DescriptionABL-IN-29 is a picomolar ABL kinase inhibitor with IC50 of 0.06/0.11 nM for wt ABL and ABL T315I respectively.
-
DescriptionABL-IN-29 is a picomolar ABL kinase inhibitor with IC50 of 0.06/0.11 nM for wt ABL and ABL T315I respectively.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetBcr-Abl
-
RecptorBcr-Abl
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1430719-97-3
-
Formula Weight327.402
-
Molecular FormulaC17H17N3O2S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name1-ethyl-3-(6-(2-methoxyphenyl)benzo[d]thiazol-2-yl)urea
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Park H, et al. J Am Chem Soc. 2013 Jun 5;135(22):8227-37.
molnova catalog
related products
-
Nilotinib
A potent, selective, orally available inhibitor of both native and mutant Bcr-Abl with IC50 of 20-80 nM.
-
CHMFL-ABL-053
CHMFL-ABL-053 is a potent, selective and orally available Bcr-Abl/Src/p38 kinase inhibitor with IC50 of 70/62/90 nM.
-
CHMFL-ABL-039
CHMFL-ABL-039 is a type II native ABL kinase and drug-resistant V299L mutant BCR-ABL inhibitor (IC50s: 7.9 nM and 27.9 nM) used in the research of chronic myeloid leukemia.
